dc.contributor | Departament de Salut |
dc.date.accessioned | 2019-04-04T09:52:23Z |
dc.date.available | 2019-04-04T09:52:23Z |
dc.date.issued | 2018-11-28 |
dc.identifier.citation | Cladribina per al tractament de l'esclerosi múltiple en pacients adults. Barcelona: Servei Català de la Salut; 2018. |
dc.identifier.uri | https://hdl.handle.net/11351/4027 |
dc.description | Cladribine; Multiple sclerosis; Adult patients |
dc.description.abstract | Multiple sclerosis (MS) is a chronic central nervous system (CNS) disease that is
It is characterized by inflammation, demyelination, glial scarring and neuroaxonal degeneration. Its etiology is not entirely known, although it is thought to be an autoimmune disease triggered by an unknown environmental factor associated with a genetic predisposition. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.relation.ispartof | Programa d'harmonització farmacoterapèutica, Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments - Assaigs clínics |
dc.subject | Citotoxicitat |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | Cladribine |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | Cladribina per al tractament de l'esclerosi múltiple en pacients adults |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | cladribina |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | evaluación de medicamentos |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |